Construction and Validation of a Progression‐Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification

Abstract

To investigate the clinical characteristics of newly diagnosed multiple myeloma (NDMM) patients with 1q21 gain/amplification (1q21+), construct and validate a progression‐free survival (PFS) prediction model, and explore the clinical implications of model‐based risk stratification.